{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T02:23:45Z","timestamp":1771035825372,"version":"3.50.1"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T00:00:00Z","timestamp":1621296000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK040561"],"award-info":[{"award-number":["P30DK040561"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK040561"],"award-info":[{"award-number":["P30DK040561"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI060354"],"award-info":[{"award-number":["P30AI060354"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30AI060354"],"award-info":[{"award-number":["P30AI060354"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01AI115711"],"award-info":[{"award-number":["U01AI115711"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01DK108370"],"award-info":[{"award-number":["R01DK108370"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK040561"],"award-info":[{"award-number":["P30DK040561"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005294","name":"Massachusetts General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005294","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>NAFLD is a leading comorbidity in HIV with an exaggerated course compared to the general population. Tesamorelin has been demonstrated to reduce liver fat and prevent fibrosis progression in HIV-associated NAFLD. We further showed that tesamorelin downregulated hepatic gene sets involved in inflammation, tissue repair, and cell division. Nonetheless, effects of tesamorelin on individual plasma proteins pertaining to these pathways are not known. Leveraging our prior randomized-controlled trial and transcriptomic approach, we performed a focused assessment of 9 plasma proteins corresponding to top leading edge genes within differentially modulated gene sets. Tesamorelin led to significant reductions in vascular endothelial growth factor A (VEGFA, log<jats:sub>2<\/jats:sub>-fold change \u2212\u20090.20\u2009\u00b1\u20090.35 vs. 0.05\u2009\u00b1\u20090.34, <jats:italic>P<\/jats:italic>\u2009=\u20090.02), transforming growth factor beta 1 (TGFB1, \u2212\u20090.35\u2009\u00b1\u20090.56 vs. \u2212\u20090.05\u2009\u00b1\u20090.43, <jats:italic>P<\/jats:italic>\u2009=\u20090.05), and macrophage colony stimulating factor 1 (CSF1, \u2212\u20090.17\u2009\u00b1\u20090.21 vs. 0.02\u2009\u00b1\u20090.20, <jats:italic>P<\/jats:italic>\u2009=\u20090.004) versus placebo. Among tesamorelin-treated participants, reductions in plasma VEGFA (<jats:italic>r<\/jats:italic>\u2009=\u20090.62, <jats:italic>P<\/jats:italic>\u2009=\u20090.006) and CSF1 (<jats:italic>r<\/jats:italic>\u2009=\u20090.50, <jats:italic>P<\/jats:italic>\u2009=\u20090.04) correlated with a decline in NAFLD activity score. Decreases in TGFB1 (<jats:italic>r<\/jats:italic>\u2009=\u20090.61, <jats:italic>P<\/jats:italic>\u2009=\u20090.009) and CSF1 (<jats:italic>r<\/jats:italic>\u2009=\u20090.64, <jats:italic>P<\/jats:italic>\u2009=\u20090.006) were associated with reduced gene-level fibrosis score. Tesamorelin suppressed key angiogenic, fibrogenic, and pro-inflammatory mediators. CSF1, a regulator of monocyte recruitment and activation, may serve as an innovative therapeutic target for NAFLD in HIV.\n<\/jats:p><jats:p>Clinical Trials Registry Number: NCT02196831<\/jats:p>","DOI":"10.1038\/s41598-021-89966-y","type":"journal-article","created":{"date-parts":[[2021,5,18]],"date-time":"2021-05-18T10:06:23Z","timestamp":1621332383000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Delineating tesamorelin response pathways in HIV-associated NAFLD using a targeted proteomic and transcriptomic approach"],"prefix":"10.1038","volume":"11","author":[{"given":"Lindsay T.","family":"Fourman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takara L.","family":"Stanley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James M.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shannan J. Ho","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meghan N.","family":"Feldpausch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Autumn","family":"Boutin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabel","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colin M.","family":"McClure","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen E.","family":"Corey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Torriani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Kleiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Colleen M.","family":"Hadigan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond T.","family":"Chung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven K.","family":"Grinspoon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,18]]},"reference":[{"key":"89966_CR1","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/QAD.0000000000001504","volume":"31","author":"JB Maurice","year":"2017","unstructured":"Maurice, J. B. et al. Prevalence and risk factors of nonalcoholic fatty liver disease in HIV-monoinfection. AIDS 31, 1621\u20131632. https:\/\/doi.org\/10.1097\/QAD.0000000000001504 (2017).","journal-title":"AIDS"},{"key":"89966_CR2","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1089\/aid.2015.0147","volume":"32","author":"JR Koethe","year":"2016","unstructured":"Koethe, J. R. et al. Rising obesity prevalence and weight gain among adults starting antiretroviral therapy in the United States and Canada. AIDS Res. Hum. Retroviruses 32, 50\u201358. https:\/\/doi.org\/10.1089\/aid.2015.0147 (2016).","journal-title":"AIDS Res. Hum. Retroviruses"},{"key":"89966_CR3","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1097\/QAD.0000000000001248","volume":"30","author":"PM Grant","year":"2016","unstructured":"Grant, P. M. et al. Long-term body composition changes in antiretroviral-treated HIV-infected individuals. AIDS 30, 2805\u20132813. https:\/\/doi.org\/10.1097\/QAD.0000000000001248 (2016).","journal-title":"AIDS"},{"key":"89966_CR4","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/apt.13052","volume":"41","author":"I Vodkin","year":"2015","unstructured":"Vodkin, I., Valasek, M., Bettencourt, R., Cachay, E. & Loomba, R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case\u2013control study. Aliment. Pharmacol. Ther. 41, 368\u2013378 (2015).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"89966_CR5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa382","author":"LT Fourman","year":"2020","unstructured":"Fourman, L. T. et al. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD. Clin. Infect. Dis. https:\/\/doi.org\/10.1093\/cid\/ciaa382 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"89966_CR6","doi-asserted-by":"publisher","first-page":"53","DOI":"10.21037\/tgh.2019.06.06","volume":"4","author":"VW Wong","year":"2019","unstructured":"Wong, V. W. & Singal, A. K. Emerging medical therapies for non-alcoholic fatty liver disease and for alcoholic hepatitis. Transl. Gastroenterol. Hepatol. 4, 53. https:\/\/doi.org\/10.21037\/tgh.2019.06.06 (2019).","journal-title":"Transl. Gastroenterol. Hepatol."},{"key":"89966_CR7","doi-asserted-by":"publisher","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","volume":"6","author":"TL Stanley","year":"2019","unstructured":"Stanley, T. L. et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV 6, e821\u2013e830. https:\/\/doi.org\/10.1016\/S2352-3018(19)30338-8 (2019).","journal-title":"Lancet HIV"},{"key":"89966_CR8","doi-asserted-by":"publisher","unstructured":"Fourman, L. T. et al. Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. JCI Insight 5, e140134, https:\/\/doi.org\/10.1172\/jci.insight.140134 (2020).","DOI":"10.1172\/jci.insight.140134"},{"key":"89966_CR9","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner, D. E. et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41, 1313\u20131321. https:\/\/doi.org\/10.1002\/hep.20701 (2005).","journal-title":"Hepatology"},{"key":"89966_CR10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1016\/j.cels.2015.12.004","volume":"1","author":"A Liberzon","year":"2015","unstructured":"Liberzon, A. et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 1, 417\u2013425. https:\/\/doi.org\/10.1016\/j.cels.2015.12.004 (2015).","journal-title":"Cell Syst."},{"key":"89966_CR11","doi-asserted-by":"publisher","first-page":"12541","DOI":"10.1038\/s41598-019-48746-5","volume":"9","author":"SA Hoang","year":"2019","unstructured":"Hoang, S. A. et al. Gene expression predicts histological severity and reveals distinct molecular profiles of nonalcoholic fatty liver disease. Sci. Rep. 9, 12541. https:\/\/doi.org\/10.1038\/s41598-019-48746-5 (2019).","journal-title":"Sci. Rep."},{"key":"89966_CR12","first-page":"543","volume":"1","author":"M Kitade","year":"2008","unstructured":"Kitade, M. et al. Neovascularization and oxidative stress in the progression of non-alcoholic steatohepatitis. Mol. Med. Rep. 1, 543\u2013548 (2008).","journal-title":"Mol. Med. Rep."},{"key":"89966_CR13","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.cyto.2012.05.001","volume":"59","author":"S Coulon","year":"2012","unstructured":"Coulon, S. et al. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 59, 442\u2013449. https:\/\/doi.org\/10.1016\/j.cyto.2012.05.001 (2012).","journal-title":"Cytokine"},{"key":"89966_CR14","doi-asserted-by":"publisher","first-page":"212","DOI":"10.4321\/s1130-01082008000400004","volume":"100","author":"A Cay\u00f3n","year":"2008","unstructured":"Cay\u00f3n, A., Crespo, J., Guerra, A. R. & Pons-Romero, F. Gene expression in obese patients with non-alcoholic steatohepatitis. Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 100, 212\u2013218. https:\/\/doi.org\/10.4321\/s1130-01082008000400004 (2008).","journal-title":"Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva"},{"key":"89966_CR15","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1002\/hep.26219","volume":"57","author":"S Coulon","year":"2013","unstructured":"Coulon, S. et al. Role of vascular endothelial growth factor in the pathophysiology of nonalcoholic steatohepatitis in two rodent models. Hepatology 57, 1793\u20131805. https:\/\/doi.org\/10.1002\/hep.26219 (2013).","journal-title":"Hepatology"},{"key":"89966_CR16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1111\/febs.13665","volume":"283","author":"I Fabregat","year":"2016","unstructured":"Fabregat, I. et al. TGF-\u03b2 signalling and liver disease. FEBS J. 283, 2219\u20132232. https:\/\/doi.org\/10.1111\/febs.13665 (2016).","journal-title":"FEBS J."},{"key":"89966_CR17","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/hep.26698","volume":"59","author":"L Yang","year":"2014","unstructured":"Yang, L. et al. Transforming growth factor beta signaling in hepatocytes participates in steatohepatitis through regulation of cell death and lipid metabolism in mice. Hepatology 59, 483\u2013495. https:\/\/doi.org\/10.1002\/hep.26698 (2014).","journal-title":"Hepatology"},{"key":"89966_CR18","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1111\/j.1478-3231.2006.01337.x","volume":"26","author":"A Cay\u00f3n","year":"2006","unstructured":"Cay\u00f3n, A., Crespo, J., Mayorga, M., Guerra, A. & Pons-Romero, F. Increased expression of Ob-Rb and its relationship with the overexpression of TGF-beta1 and the stage of fibrosis in patients with nonalcoholic steatohepatitis. Liver Int. 26, 1065\u20131071. https:\/\/doi.org\/10.1111\/j.1478-3231.2006.01337.x (2006).","journal-title":"Liver Int."},{"key":"89966_CR19","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/nrd.2016.231","volume":"16","author":"JA Hamilton","year":"2016","unstructured":"Hamilton, J. A., Cook, A. D. & Tak, P. P. Anti-colony-stimulating factor therapies for inflammatory and autoimmune diseases. Nat. Rev. Drug Discov. 16, 53\u201370. https:\/\/doi.org\/10.1038\/nrd.2016.231 (2016).","journal-title":"Nat. Rev. Drug Discov."},{"key":"89966_CR20","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.1053\/j.gastro.2015.08.053","volume":"149","author":"BM Stutchfield","year":"2015","unstructured":"Stutchfield, B. M. et al. CSF1 restores innate immunity after liver injury in mice and serum levels indicate outcomes of patients with acute liver failure. Gastroenterology 149, 1896\u20131909. https:\/\/doi.org\/10.1053\/j.gastro.2015.08.053 (2015).","journal-title":"Gastroenterology"},{"key":"89966_CR21","first-page":"657","volume":"139","author":"M Naito","year":"1991","unstructured":"Naito, M. et al. Abnormal differentiation of tissue macrophage populations in \u201costeopetrosis\u201d (op) mice defective in the production of macrophage colony-stimulating factor. Am. J .Pathol 139, 657\u2013667 (1991).","journal-title":"Am. J .Pathol"},{"key":"89966_CR22","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.ajpath.2011.03.029","volume":"179","author":"ZA Radi","year":"2011","unstructured":"Radi, Z. A. et al. Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am. J. Pathol. 179, 240\u2013247. https:\/\/doi.org\/10.1016\/j.ajpath.2011.03.029 (2011).","journal-title":"Am. J. Pathol."},{"key":"89966_CR23","doi-asserted-by":"publisher","first-page":"40161","DOI":"10.1074\/jbc.M112.417014","volume":"287","author":"AC Tosello-Trampont","year":"2012","unstructured":"Tosello-Trampont, A. C., Landes, S. G., Nguyen, V., Novobrantseva, T. I. & Hahn, Y. S. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-\u03b1 production. J Biol Chem 287, 40161\u201340172. https:\/\/doi.org\/10.1074\/jbc.M112.417014 (2012).","journal-title":"J Biol Chem"},{"key":"89966_CR24","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.3389\/fimmu.2020.01169","volume":"11","author":"H Li","year":"2020","unstructured":"Li, H. et al. Crosstalk Between Liver Macrophages and Surrounding Cells in Nonalcoholic Steatohepatitis. Front. Immunol. 11, 1169. https:\/\/doi.org\/10.3389\/fimmu.2020.01169 (2020).","journal-title":"Front. Immunol."},{"key":"89966_CR25","first-page":"291","volume":"140","author":"ME Rosenfeld","year":"1992","unstructured":"Rosenfeld, M. E. et al. Macrophage colony-stimulating factor mRNA and protein in atherosclerotic lesions of rabbits and humans. Am J Pathol 140, 291\u2013300 (1992).","journal-title":"Am J Pathol"},{"key":"89966_CR26","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jacc.2018.04.067","volume":"72","author":"J Sjaarda","year":"2018","unstructured":"Sjaarda, J. et al. Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. J Am Coll Cardiol 72, 300\u2013310. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.067 (2018).","journal-title":"J Am Coll Cardiol"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89966-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89966-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89966-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T08:33:56Z","timestamp":1670056436000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-89966-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,18]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["89966"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-89966-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,18]]},"assertion":[{"value":"1 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.T.F. has served as a consultant for Theratechnologies, Inc. T.L.S. has served as a consultant for Theratechnologies, and reports research funding from Novo Nordisk, Inc. J.M.B. and S.J.H.S. report research funding from Boehringer Ingelheim. S.J.H.S. also reports research funding from AstraZeneca. K.E.C. reports research funding from Boehringer Ingelheim and has served as a consultant to Novo Nordisk, Inc, and Bristol Myers Squibb. R.T.C. reports research funding from Abbvie, Gilead, Merck, Bristol Myers Squibb, Boehringer Ingelheim, Janssen, and Roche. S.K.G. has served as a consultant (personal) and currently serves as a consultant through an Institutional Consulting Agreement with Theratechnologies. The Mass General Hospital has a royalty and license agreement with Theratechnologies for Tesamorelin. Dr. Grinspoon is the inventor on a patent for GHRH or Analogues Thereof For Use in Treatment of Hepatic Disease (application 16832128). M.N.F., A.B., I.Z., C.M.M., M.T., D.E.K., and C.M.H. report no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10485"}}